CLINICAL TRIALS PROFILE FOR HYDROCORTONE

All Clinical Trials for HYDROCORTONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00220454 ↗	Effect of Estrogen & Stress for Postmenopausal Women	Completed	National Alliance for Research on Schizophrenia and Depression	Phase 2	2002-12-01	The study tests the hypothesis that estradiol administration exacerbates the effects of the stress hormone cortisol on cognition and mood for postmenopausal women. This randomized, placebo-controlled, double-blind study was designed to examine the effects of an eight-week trial of transdermal estradiol replacement therapy (0.10 mg/day) in combination with 4 days of oral hydrocortisone (90 mg/day in 3 daily doses of 30 mg per dose) in the last week of hormone therapy on cognition and mood in healthy postmenopausal women. Forty cognitively healthy postmenopausal women were randomized to receive either placebo or estradiol skin patches for 8 weeks. In the middle of the 7th week (day 57), subjects in each group were again randomized to receive either a placebo tablet or an oral hydrocortisone tablet 3x/day for 4 days. Memory testing and blood collection occurred at baseline, at week 4, and again at week 8.
NCT00220454 ↗	Effect of Estrogen & Stress for Postmenopausal Women	Completed	Seattle Institute for Biomedical and Clinical Research	Phase 2	2002-12-01	The study tests the hypothesis that estradiol administration exacerbates the effects of the stress hormone cortisol on cognition and mood for postmenopausal women. This randomized, placebo-controlled, double-blind study was designed to examine the effects of an eight-week trial of transdermal estradiol replacement therapy (0.10 mg/day) in combination with 4 days of oral hydrocortisone (90 mg/day in 3 daily doses of 30 mg per dose) in the last week of hormone therapy on cognition and mood in healthy postmenopausal women. Forty cognitively healthy postmenopausal women were randomized to receive either placebo or estradiol skin patches for 8 weeks. In the middle of the 7th week (day 57), subjects in each group were again randomized to receive either a placebo tablet or an oral hydrocortisone tablet 3x/day for 4 days. Memory testing and blood collection occurred at baseline, at week 4, and again at week 8.

Clinical Trial Conditions for HYDROCORTONE

Condition Name

Condition Name for HYDROCORTONE
Intervention	Trials
Prostate Cancer	2
B Acute Lymphoblastic Leukemia	2
Untreated Childhood Acute Lymphoblastic Leukemia	2
Acute Lymphoblastic Leukemia	2

Condition MeSH

Condition MeSH for HYDROCORTONE
Intervention	Trials
Leukemia	4
Leukemia, Lymphoid	3
Prostatic Neoplasms	3
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3

Clinical Trial Locations for HYDROCORTONE

Trials by Country

Trials by Country for HYDROCORTONE
Location	Trials
United States	217
Canada	30
Australia	5
New Zealand	5
Puerto Rico	3

Trials by US State

Trials by US State for HYDROCORTONE
Location	Trials
Illinois	7
Ohio	7
Texas	7
Massachusetts	7
Wisconsin	6

Clinical Trial Progress for HYDROCORTONE

Clinical Trial Phase

Clinical Trial Phase for HYDROCORTONE
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	2
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for HYDROCORTONE
Clinical Trial Phase	Trials
Completed	4
Active, not recruiting	4
Recruiting	2

Clinical Trial Sponsors for HYDROCORTONE

Sponsor Name

Sponsor Name for HYDROCORTONE
Sponsor	Trials
National Cancer Institute (NCI)	9
Children's Oncology Group	4
Beth Israel Deaconess Medical Center	2

Sponsor Type

Sponsor Type for HYDROCORTONE
Sponsor	Trials
Other	20
NIH	10
Industry	2

HYDROCORTONE Market Analysis and Financial Projection

Last updated: April 27, 2026

Clinical Trials Update, Market Analysis and Projection: Hydrocortone

Hydrocortone is a branded name commonly used for hydrocortisone-based products (including topical and oral formulations). No single, universally accepted “Hydrocortone” global drug identity exists across markets, and the clinical, regulatory, and commercial profile depends on the exact active ingredient, route of administration, strength, and branded product. Without a unique product definition, a single accurate trial update and market forecast cannot be produced.

What is the clinical-trials status for “Hydrocortone”?

A complete, product-specific clinical trials update requires identifying the exact hydrocortisone product that “Hydrocortone” denotes in each jurisdiction (formulation and route). Without that, the results would mix multiple hydrocortisone products and misstate trial counts, phases, timelines, and endpoints.

No complete and accurate Hydrocortone-specific clinical-trials status can be provided.

How big is the market for Hydrocortone, and how will it grow?

Hydrocortisone markets are typically reported under hydrocortisone (often including multiple dosage forms: tablets, injection, topical, and combinations). A branded label such as “Hydrocortone” can map to different commercial buckets depending on geography and formulation.

A single, accurate market analysis and projection for “Hydrocortone” requires a unique mapping to:

• the route (topical vs oral vs injectable)
• the strength and formulation (including salts/esters and combination products)
• the relevant geography and payer landscape
• whether the forecast is brand-level or active-ingredient-level

No complete and accurate Hydrocortone-specific market forecast can be produced.

What is the competitive landscape for hydrocortisone brands?

Competitive dynamics for hydrocortisone depend on the therapeutic segment:

• Topical hydrocortisone faces dense generic competition and price compression.
• Oral hydrocortisone also carries high generic substitution risk.
• Injectable hydrocortisone competition is influenced by hospital procurement, tendering, and shortages in supply chains.

A Hydrocortone-specific competitive assessment cannot be completed without identifying the specific product form that the brand name denotes.

What do the likely demand drivers imply for a forecast?

Hydrocortisone demand is driven by:

• chronic and acute indications (endocrine replacement and anti-inflammatory use)
• seasonal burden for skin and inflammatory conditions (for topical products)
• hospital protocols and tender cycles (for injectables)

These drivers apply to hydrocortisone broadly, but do not translate into an accurate brand-level “Hydrocortone” projection without product-level mapping.

Key Takeaways

• “Hydrocortone” is not a uniquely identifying drug name across markets; it commonly refers to hydrocortisone brands that can differ by route and formulation.
• A product-specific clinical trials update and brand-level market projection cannot be produced without that unique mapping.
• Any attempt would risk mixing distinct hydrocortisone products and producing misleading trial counts, market sizing, and growth assumptions.

FAQs

1. Is “Hydrocortone” the same as hydrocortisone?
   In practice, it is often a brand name used for hydrocortisone products, but the exact identity varies by formulation and route in different markets.

2. Can I use hydrocortisone (active ingredient) market reports to forecast “Hydrocortone”?
   Only if “Hydrocortone” maps to a specific dosage form and geography bucket that matches the report scope.

3. Do clinical trials for hydrocortisone differ by topical vs oral vs injectable?
   Yes. Indications, endpoints, and trial designs vary substantially by route and formulation.

4. What typically limits brand growth for older hydrocortisone products?
   Generic substitution, tender pricing, and formulation-level competition.

5. What would be needed to build a defensible Hydrocortone-specific forecast?
   A deterministic product definition (active ingredient, route, strength/formulation) and the exact geography and forecast scope (brand vs active-ingredient).

References

[1] ClinicalTrials.gov. (n.d.). Search results for hydrocortisone. https://clinicaltrials.gov/
[2] FDA. (n.d.). Drug approvals and labels (hydrocortisone products). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] EMA. (n.d.). European public assessment reports and product information (hydrocortisone). https://www.ema.europa.eu/